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Table 1. Pharmacological differences between 
steroidal and nonsteroidal antiandrogens
Steroidal antiandrogens Non-steroidal antiandrogens
Block androgen binding to 
its specific receptor
Have progestational 
properties
Suppress gonadotropin
Serum luteinising hormone 
levels are decreased
Testicular testosterone 
synthesis is reduced
Block androgen binding to 
its specific receptor
Do not have progestational 
properties
Do not suppress 
gonadotropin
Serum luteinising hormone  
levels are not reduced
Testicular testosterone  
synthesis is not reduced
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AbstrAct
Selective Androgen Receptor Modulators (SARMs) are the novel class of the androgen receptors (AR), often 
called tissue-selective AR ligands. Discovery of SARMs will give a possibility to the alternative therapy for 
androgens therapy (osteoporosis, prostate cancer, muscle wasting). SARMs should have high specificity for 
the AR, tissue-selective pharmacokinetic activities, improved oral bioavailability and pharmacokinetic profile 
which allows once-a-day administration [1].
Example of SARMs is flutamide (flutamidum, Eulexin, imid 2-methyl-N-{4-nitro-(3-trifluoromethyl)-phe-
nyl]-propionic acid), a synthetic nonsteroidal drug that is a competitive antagonist of the androgen receptor. 
SARMs were recognized as forbidden substances by the World Anti-Doping Agency (WADA) and since 2004 
they are on the Prohibited List. To point on the Prohibited List 2019 “Substance and methods prohibited at 
all time (in- and out-of-competition)” SARMs belong to group  S1. 2. Other Anabolic Agents, and  to group 
S4. Hormone Antagonist and Modulators [2].
The main role of an anti-doping laboratory is to analyse and to determine whether a given substance should 
be prohibited in sport. The principal analyses of SARMs and Specific Steroid Substance are a different variant 
of chromatography (LC — liquid or GC — gas) with many detection techniques (MS — mainly mass spec-
trometer, MS/MS — tandem mass spectrometer).
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IntroDuctIon
clinical applications of sArMs
SARMs can be divided into two different classes 
compounds: nonsteroidal and steroidal antiandro-
gens (Tab. 1). The major goal in the development 
of SARMs is to prevent the undesirable side-effects 
of treatment by improving the tissue selectivity of 
the ligands. This would greatly enlarge the clinical 
applications of these ligands beyond primary and 
secondary hypogonadism. Other applications of 
SARMs include hormone-replacement therapy, os-
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teoporosis, muscle wasting, male contraception and 
prostate cancer. The dual effects of SARMs in muscle 
and bone might be particularly advantageous for 
the treatment of osteoporosis because an increase in 
muscle mass and strength might help rebuild bone 
mass and also reduce the risk of fracture because of 
a reduced chance of fall [1].
The biggest advantage of anabolic SARMs is that 
these ligands might be safe to use in women ther-
apy.  Improving tissue selectivity, SARMs that keep 
steady the anabolic actions of androgens without 
causing the virilizing effects associated with tradi-
tional androgen therapies, open the door to poten-
tial applications in hormone-replacement therapy 
(HRT) in postmenopausal women, osteoporosis or 
sexual functions. 
Flutamide (amid 2-methyl-N-[-4-nitro-(3-trif-
luoromethyl)-phenyl]-propionic acid; Fig 1.) is one 
of the compound rates to nonsteroidal antiandro-
gens. It’s easily absorbed from the digestive system, 
and it’s mainly metabolised to hydroxyl derivative. 
Primarily used to treat prostate cancer. Minority clin-
ical effect has cyproterone acetate (steroidal antian-
drogen). It is a derivative of synthetic progesterone 
drug with very strong androgen action, curbed an-
drogen production in the renal cortex and blocked 
testosterone binding receptors.
DIscussIon
Specific Steroids Substance are a class of compounds 
named antioestrogens. Antioestrogens can be divid-
ed into two different  groups: selective antioestro-
gen receptor modulators (SERMs) and aromatase 
inhibitors. In 1958, Lerner and co-workers pub-
lished their landmark paper on the pharmacological 
properties of the first nonsteroidal antioestrogen 
ethamoxytriphetol or MER-25. Lerner later wrote, 
“the compound was appealing not only because it 
completely inhibited the uterine response to oestra-
diol (E2)b but also because it was devoid of uterine 
stimulatory properties. Antioestrogens are a class 
of medication that acts on the oestrogen receptor 
compounds in cytoplasmic cells, especially sensitive 
for oestrogens (teat cells, womb cells, hypothala-
mus, pituitary gland) [3].
Tamoxifen, a first-generation selective oestrogen 
receptor modulator, was introduced as a treatment 
option for breast cancer more than three decades 
ago. It is now used among women of all ages for 
the treatment of breast cancer, irrespective of cancer 
stage. Tamoxifen is also approved by the U.S. Food 
and Drug Administration as a chemo preventive 
agent against breast cancer and is now prescribed 
to women at high risk of this disease. However, 
the drug has serious side effects, like endometrial 
cancer and venous thrombotic events which may 
be dose-dependent or related to the accumulated 
dose [4].
Antiandrogens and antioestrogens have gained 
universal recognition as prohibited substances. by 
WADA. 
In the year 2019 they are classified as:
Group  S1. 2. Other Anabolic Agents, including 
but not limited to:
Clenbuterol, selective androgen receptor mod-
ulators (SARMs), tibolone, zeranol, zilpaterol and 
Group S4.vHormone Antagonists and modulators
fIGure 1. Chemical structure of anti-androgens
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Table 2. Substances Identified as AAFs* in Each 
Drug Class in ADAMS (All Sports) [6]
S.4 Hormone and 
Metabolic Modulators Occurrences
% within the drug 
class
Clomifene
Tamoxifene
Anastrozol
Letrozol
6-oxo-androstenedione
Raloxifene
65
64
40
22
1
1
20%
20%
12%
7%
0.3%
0.3%
* The Adverse Analytical Findings (AAFs) in these tables are not to be confused with 
adjudicated or sanctioned Anti-Doping Rule Violations (ADRVs), as the figures given 
in this report may contain findings that underwent the Therapeutic Use Exemption 
(TUE) approval process or multiple findings on the same Athlete
accredited laboratories are using all selective and 
sensitive methods, like liquid and gas chromatog-
raphy with selective detectors and mass spectrom-
eters. The key to a high stand of art in anti-doping 
analysis is to detect all parents compounds and also 
all metabolites. All classes of these compounds are 
on the Prohibited List [2].
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The following classes are prohibited:
1) Aromatase inhibitors including, but not limited 
to: anastrozole, letrozole, aminoglutethimide, 
exemestane, formestane, testolactone.
2) Selective oestrogen receptor modulators (SERMs) 
including, but not limited to: raloxifene, tamox-
ifen, toremifene.
3) Other antiestrogenic substances including, but 
not limited to: clomiphene, cyclofenil, fulves-
trant.
4) Agents modifying myostatin function(s) includ-
ing but not limited to: myostatin inhibitors.
Antiandrogens and antioestrogens are popular 
in sports circle for a few years. They are very popular 
in male sports. In doping world antiandrogenic sub-
stances are called as mask substance by the influ-
ence of the decrease of androgens, thereby chang-
ing  concentration of steroid profile.antiestrogens, 
however, such as tamoxifen or clomiphene, have 
stimulating effects on the secretion of hypophysic 
gonadotropic hormones. They are mainly used in 
the treatment of infertility. In males, antiestrogenic 
substances may cause an increase of the endog-
enous production of androgens. Athletes may be 
encouraged to treat the adverse effects of extensive 
abuse of anabolic androgenic steroids (e.g. suppres-
sion of androgens, gynecomastia) by using antiest-
rogenic drugs [5]. WADA is publishing the statistic 
of the prohibited substances Identified in Each Drug 
Class (Tab. 2) [6].
conclusIons
To analyse Selective Androgen Receptor Modulators 
and other Specific Steroids Substance all WADA 
